Drugmaker Merck reports quarterly results Thursday morning as fears grow over the expiration of the patent on its top-selling ...

Groundbreaking longevity research initiative brings together leading scientists and institutions to decode the genetic basis ...

Merck & Co. Inc. closed 41.34% below its 52-week high of $134.63, which the company achieved on June 25th.

The stock's rise snapped a three-day losing streak.

In the last two years, Merck has beaten EPS estimates 88% of the time, and revenue estimates 100% of the time. Meanwhile, ...

Merck is growing pharma sales and expanding margins, led by strong KEYTRUDA performance and cost discipline. Read more about ...

We recently published a list of 20 Best Stock To Buy According to Marjorie Taylor Greene. In this article, we are going to ...

Merck & Co reports Q1 earnings on Thursday with EPS of $2.14 and revenue of $15.33B expected. Despite a 38.04% drop in stock ...

He is the head of HHS, and yet he continues to spout untested, unproven therapies and has only given a very lukewarm ...

We recently compiled a list of Billionaire Prem Watsa’s 10 Stock Picks With Highest Potential. In this article, we are going ...

The Dow Jones Industrial Average (DJIA) declined on Thursday despite many stocks on the index rising. Instead, a few major ...

Merck & Company (MRK – Research Report) received a Hold rating and an $85.00 price target from Cantor Fitzgerald analyst Carter Gould ...